31 August 2021
University Hospitals Coventry and Warwickshire NHS Trust (UHCW) is undertaking a world-leading drug trial that could bring relief to sufferers of back pain.
UHCW is conducting its first commercial phase one clinical trial, testing an injectable antibiotic formulation (PP353) for chronic low back pain (CLBP) caused by bacterial infection.
Just three people have tried the drug, which is delivered directly into the spine via injection.
Scot Harris, who has suffered with CLBP for five years, volunteered for the trial at UHCW – and the early signs are promising.
“The pain has dramatically reduced,” said Scot, 44. “I can go swimming again and lead a more normal life that people take for granted. But for me they are blessings.
“I would like children one day but what I didn’t want to be was one of those fathers who can only do so much because you are so debilitated by the pain.”
Pharmaceutical company Persica is running the trial through the National Institute for Health Research (NIHR) Coventry and Warwickshire Clinical Research Facility (CRF), based at University Hospital, Coventry, and the NIHR Lancashire Clinical Research Facility at the Royal Preston Hospital. The NIHR is a major funder of global health research and training.
Professor Chris Imray, Director of Coventry NIHR CRF, said: “This is the latest step in our ongoing quest to offer early phase research opportunities to our patients.
“Complex studies like this can only be delivered through a real team effort and we have to thank everyone who is making this study happen here; especially the staff in theatres, Ward 53, Pharmacy and Radiology.”
Several studies have shown prolonged use of oral antibiotics can be more effective in relieving CLBP due to infection than best practice medical or surgical care.
However, prolonged oral antibiotic therapy can lead to unwanted side effects and increases the chance of developing antibiotic resistance.
PP353 offers a more effective delivery method, reducing systemic exposure and the likelihood of gastrointestinal side effects.
Steve Ruston, Chief Executive Officer of Persica Pharmaceuticals, said: “We believe PP353 has the potential to deliver benefit to millions of patients suffering from CLBP.”
Scot must visit for check-ups once a month for the next year, when the results of the trial will be analysed.
Back
Visit the UHCW CHarity Website
Please ensure you have a current blood test request form, if not please contact your hospital consultant or GP and they will post one to you. Unfortunately, your blood test will need to be rescheduled if you do not have a blood test request form when you come to a Blood Test clinic.
All blood tests are by appointment, please book an appointment using the Book Online button below.
If you have an appointment and cannot attend, please remember to cancel or reschedule your appointment so that someone else can use the time slot that you no longer need.
If you cannot book an appointment online, family and friends may be able to help – you can book appointments for more than one person from one account. Booking online is the quickest way to make an appointment.
If this is not possible, there is a telephone line for those who cannot book online. Please call 02476 153546 between 8am and 1pm Monday to Friday, excluding Bank Holidays.